Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2018.1489255
Abstract: Abstract Aim: In active relapsing remitting multiple sclerosis (RRMS) patients requiring second-line treatment, the Dutch National Health Care Institute (ZiN) has not stated a preference for either alemtuzumab, fingolimod, or natalizumab. The aim was to… read more here.
Keywords: cost minimization; treatment; minimization analysis; fingolimod natalizumab ... See more keywords
A cost-minimization analysis of large overjet reduction with two removable functional appliances based on a randomized controlled trial
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Orthodontics"
DOI: 10.1093/ejo/cjx077
Abstract: Objective The purpose of this study was to assess and relate the societal costs of reducing large overjet with a prefabricated functional appliance (PFA), or a slightly modified Andresen activator (AA), using a cost-minimization analysis… read more here.
Keywords: trial; cost minimization; large overjet; minimization analysis ... See more keywords
Counting the Cost of Daptomycin Versus Vancomycin in Hospitalized Patients: A Cost Minimization Analysis
Sign Up to like & getrecommendations! Published in 2024 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae217
Abstract: Abstract Daptomycin use for gram-positive infections has increased. This cost minimization analysis aimed to determine cost and/or time savings of daptomycin over vancomycin. The estimated hospital cost savings was US$166.41 per patient, and pharmacist time… read more here.
Keywords: cost; daptomycin; minimization analysis; cost minimization ... See more keywords